nach oben

Journal of Neurology

Erschienen in:

07.02.2020 | Original Communication

Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease

Erschienen in: Journal of Neurology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Cognitive impairment is an essential feature of Huntington’s disease (HD) and dementia is a predictable outcome in all patients. However, validated instruments to assess global cognitive performance in the field of HD are lacking.

Objectives

We aimed to explore the utility of the Parkinson’s disease-Cognitive Rating Scale (PD-CRS) for the screening of global cognition in HD.

Methods

A multicenter cohort of 132 HD patients at different disease stages and 33 matched healthy controls were classified as having preserved cognition, mild cognitive impairment (HD-MCI) or dementia (HD-Dem) according to the Clinical Dementia Rating and Functional Independence Score. The PD-CRS and the Mini-Mental State Examination were administered. Receiver operating characteristic curve analysis was used to determine optimal cutoffs to differentiate patients according to their cognitive status.

Results

A PD-CRS cutoff score ≤ 81/82 was optimal to detect HD-MCI (sensitivity = 93%; specificity = 80%; area under the curve (AUC) = 0.940), and ≤ 63/64 was optimal to detect HD-Dem (sensitivity = 90%; specificity = 87%; AUC = 0.933). MMSE scores failed to show robust psychometric properties in this context.

Discussion

The PD-CRS is a valid and reliable instrument to assess global cognition in HD in routine clinical care and clinical trials.

Nur mit Berechtigung zugänglich

Walker FO (2007) Huntington's disease. Lancet 369(9557):218–228. https://doi.org/10.1016/S0140-6736(07)60111-1CrossRefPubMed

Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, Reilmann R, Unschuld PG, Wexler A, Margolis RL, Tabrizi SJ (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10(4):204–216. https://doi.org/10.1038/nrneurol.2014.24CrossRefPubMed

Paulsen JS, Miller AC, Hayes T, Shaw E (2017) Cognitive and behavioral changes in Huntington disease before diagnosis. Handb Clin Neurol 144:69–91. https://doi.org/10.1016/B978-0-12-801893-4.00006-7CrossRefPubMed

Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8(9):791–801. https://doi.org/10.1016/S1474-4422(09)70170-XCrossRefPubMedPubMedCentral

Peavy GM, Jacobson MW, Goldstein JL, Hamilton JM, Kane A, Gamst AC, Lessig SL, Lee JC, Corey-Bloom J (2010) Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov Disord 25(9):1163–1169. https://doi.org/10.1002/mds.22953CrossRefPubMedPubMedCentral

Dogan I, Eickhoff SB, Schulz JB, Shah NJ, Laird AR, Fox PT, Reetz K (2013) Consistent neurodegeneration and its association with clinical progression in Huntington's disease: a coordinate-based meta-analysis. Neuro-degener Dis 12(1):23–35. https://doi.org/10.1159/000339528CrossRef

Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B (2005) Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 65(5):745–747. https://doi.org/10.1212/01.wnl.0000174432.87383.87CrossRefPubMed

Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS (2010) Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 40(3):544–554. https://doi.org/10.1016/j.nbd.2010.07.014CrossRefPubMedPubMedCentral

Sampedro F, Martinez-Horta S, Perez-Perez J, Horta-Barba A, Lopez-Mora DA, Camacho V, Fernandez-Leon A, Gomez-Anson B, Carrio I, Kulisevsky J (2019) Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease. Eur J Nucl Med Mol Imaging 46(5):1111–1116. https://doi.org/10.1007/s00259-018-4257-zCrossRefPubMed

10.

Gregory S, Crawford H, Seunarine K, Leavitt B, Durr A, Roos RAC, Scahill RI, Tabrizi SJ, Rees G, Langbehn D, Orth M (2018) Natural biological variation of white matter microstructure is accentuated in Huntington's disease. Hum Brain Mapp. https://doi.org/10.1002/hbm.24191CrossRefPubMedPubMedCentral

11.

Paulsen JS, Long JD, Johnson HJ, Aylward EH, Ross CA, Williams JK, Nance MA, Erwin CJ, Westervelt HJ, Harrington DL, Bockholt HJ, Zhang Y, McCusker EA, Chiu EM, Panegyres PK (2014) Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front Aging Neurosci 6:78. https://doi.org/10.3389/fnagi.2014.00078CrossRefPubMedPubMedCentral

12.

Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, Jones R, Johnson H, Craufurd D, Hicks SL, Kennard C, Landwehrmeyer B, Stout JC, Borowsky B, Scahill RI, Frost C, Langbehn DR (2012) Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11(1):42–53. https://doi.org/10.1016/S1474-4422(11)70263-0CrossRefPubMed

13.

Mestre TA, Bachoud-Levi AC, Marinus J, Stout JC, Paulsen JS, Como P, Duff K, Sampaio C, Goetz CG, Cubo E, Stebbins GT, Martinez-Martin P (2018) Rating scales for cognition in Huntington's disease: critique and recommendations. Mov Disord 33(2):187–195. https://doi.org/10.1002/mds.27227CrossRefPubMed

14.

Julayanont P, McFarland NR, Heilman KM (2020) Mild cognitive impairment and dementia in motor manifest Huntington's disease: classification and prevalence. J Neurol Sci 408:116523. https://doi.org/10.1016/j.jns.2019.116523CrossRefPubMed

15.

Duff K, Paulsen J, Mills J, Beglinger LJ, Moser DJ, Smith MM, Langbehn D, Stout J, Queller S, Harrington DL (2010) Mild cognitive impairment in prediagnosed Huntington disease. Neurology 75(6):500–507. https://doi.org/10.1212/WNL.0b013e3181eccfa2CrossRefPubMedPubMedCentral

16.

Videnovic A, Bernard B, Fan W, Jaglin J, Leurgans S, Shannon KM (2010) The Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in Huntington's disease. Mov Disord 25(3):401–404. https://doi.org/10.1002/mds.22748CrossRefPubMed

17.

Ringkobing SP, Larsen IU, Jorgensen K, Vinther-Jensen T, Vogel A (2019) Cognitive screening tests in huntington gene mutation carriers: examining the validity of the mini-mental state examination and the montreal cognitive assessment. J Huntington's Dis. https://doi.org/10.3233/JHD-190350CrossRef

18.

Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A (2008) Parkinson's disease-cognitive rating scale: a new cognitive scale specific for Parkinson's disease. Mov Disord 23(7):998–1005. https://doi.org/10.1002/mds.22007CrossRefPubMed

19.

Fernandez de Bobadilla R, Pagonabarraga J, Martinez-Horta S, Pascual-Sedano B, Campolongo A, Kulisevsky J (2013) Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment. Mov Disord 28(10):1376–1383. https://doi.org/10.1002/mds.25568CrossRefPubMed

20.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 132(Pt 11):2958–2969. https://doi.org/10.1093/brain/awp245CrossRefPubMed

21.

Skorvanek M, Goldman JG, Jahanshahi M, Marras C, Rektorova I, Schmand B, van Duijn E, Goetz CG, Weintraub D, Stebbins GT, Martinez-Martin P (2018) Global scales for cognitive screening in Parkinson's disease: critique and recommendations. Mov Disord 33(2):208–218. https://doi.org/10.1002/mds.27233CrossRefPubMed

22.

Group HS (1996) Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord 11(2):136–142. https://doi.org/10.1002/mds.870110204CrossRef

23.

Shoulson I, Fahn S (1979) Huntington disease: clinical care and evaluation. Neurology 29(1):1–3. https://doi.org/10.1212/wnl.29.1.1CrossRefPubMed

24.

Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 41(5):689–692. https://doi.org/10.1002/ana.410410521CrossRefPubMed

25.

Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140:566–572CrossRef

26.

Callaghan J, Stopford C, Arran N, Boisse MF, Coleman A, Santos RD, Dumas EM, Hart EP, Justo D, Owen G, Read J, Say MJ, Durr A, Leavitt BR, Roos RA, Tabrizi SJ, Bachoud-Levi AC, Bourdet C, van Duijn E, Craufurd D (2015) Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. J Neuropsychiatry Clin Neurosci 27(1):59–64. https://doi.org/10.1176/appi.neuropsych.13070169CrossRefPubMed

27.

Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA (2013) The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease. J Neurol 260(11):2777–2785. https://doi.org/10.1007/s00415-013-7061-5CrossRefPubMed

28.

Stout JC, Queller S, Baker KN, Cowlishaw S, Sampaio C, Fitzer-Attas C, Borowsky B (2014) HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3. Mov Disord 29(10):1281–1288. https://doi.org/10.1002/mds.25964CrossRefPubMed

29.

Mickes L, Jacobson M, Peavy G, Wixted JT, Lessig S, Goldstein JL, Corey-Bloom J (2010) A comparison of two brief screening measures of cognitive impairment in Huntington's disease. Mov Disord 25(13):2229–2233. https://doi.org/10.1002/mds.23181CrossRefPubMed

30.

Coppen EM, Grond JV, Hafkemeijer A, Barkey Wolf JJH, Roos RAC (2018) Structural and functional changes of the visual cortex in early Huntington's disease. Hum Brain Mapp 39(12):4776–4786. https://doi.org/10.1002/hbm.24322CrossRefPubMedPubMedCentral

31.

Johnson EB, Rees EM, Labuschagne I, Durr A, Leavitt BR, Roos RA, Reilmann R, Johnson H, Hobbs NZ, Langbehn DR, Stout JC, Tabrizi SJ, Scahill RI (2015) The impact of occipital lobe cortical thickness on cognitive task performance: an investigation in Huntington's Disease. Neuropsychologia 79(Pt A):138–146. https://doi.org/10.1016/j.neuropsychologia.2015.10.033CrossRefPubMed

32.

Labuschagne I, Cassidy AM, Scahill RI, Johnson EB, Rees E, O'Regan A, Queller S, Frost C, Leavitt BR, Durr A, Roos R, Owen G, Borowsky B, Tabrizi SJ, Stout JC (2016) Visuospatial processing deficits linked to posterior brain regions in premanifest and early stage Huntington's disease. J Int Neuropsychol Soc 22(6):595–608. https://doi.org/10.1017/S1355617716000321CrossRefPubMed

Titel: Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease
Publikationsdatum: 07.02.2020
Erschienen in: Journal of Neurology / Ausgabe 5/2020
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-09730-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease

Abstract

Background

Objectives

Methods

Results

Discussion

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Background

Objectives

Methods

Results

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Complications in cranioplasty after decompressive craniectomy: timing of the intervention

Subjects at risk of Parkinson’s disease in health checkup examinees: cross-sectional analysis of baseline data of the NaT-PROBE study

The clinical profile of NMOSD in Australia and New Zealand

Clinical features and prognosis of late-onset neuromyelitis optica spectrum disorders in a Latin American cohort

Multiple acyl-COA dehydrogenase deficiency in elderly carriers

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie